Skip to content

Total Revenue at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$246.09M+87.0%
ALN
Alnylam PharmaceuticalsALNY
$1.17B+96.4%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$1.46M+68.6%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$31.74M+325%
Immunome logo
ImmunomeIMNM
$0-100%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$10.86M+3.8%

Other financials

Income statement

See full
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.13B+106%
Enterprise value$2.08B+100%
P/S32.2×+9.5×

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's total revenue?
Intellia Therapeutics (NTLA) reported total revenue of $15.05M in Q1 2026.
How has Intellia Therapeutics's total revenue changed year-over-year?
Intellia Therapeutics's total revenue decreased by 9.5% year-over-year, from $16.63M to $15.05M.
What is the long-term trend for Intellia Therapeutics's total revenue?
Over 4 years (2021 to 2025), Intellia Therapeutics's total revenue has grown at a 19.6% compound annual growth rate (CAGR), from $33.05M to $67.67M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.